Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Observation Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.

NCT04760990 is registered in ClinicalTrials.gov with University Hospital, Basel, Switzerland as lead sponsor.

NCT NCT04760990
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04760990 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Observation Study to Assess the Potential Impact of Disease Modifying Therapies on COVID-19 Outcomes and the Antibody Response Following an Infection With SARS-CoV-2 in Patients With Multiple Sclerosis Within the Swiss Multiple Sclerosis Cohort.
Lead sponsor
University Hospital, Basel, Switzerland
Phase
Observational
Overall status
Completed
Start date
February 1, 2021
Completion date
December 15, 2023
Enrollment
1,181 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 (severe coronavirus disease 2019), multiple sclerosis